ADC Therapeutics raises US$200m in private financing
Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors include Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.